Oncolytics Biotech Inc. to Present at Rodman & Renshaw 3rd Annual Global Healthcare Conference

Strategic Insights

May 10, 2006 — 1 min read

Oncolytics Biotech Inc., a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics, will present a corporate overview at the Rodman & Renshaw 3rd Annual Global Healthcare Conference on May 16, 2006. Dr. Brad Thompson, President and CEO, will lead the presentation at 11:55 a.m. (5:55 a.m. ET) at the Le Meridien Beach Plaza Hotel in Monte Carlo, Monaco. The event will be webcast live, allowing investors and stakeholders to participate remotely.

Key Takeaways:

Oncolytics Biotech Inc. will present a corporate overview at the Rodman & Renshaw 3rd Annual Global Healthcare Conference on May 16, 2006.
Dr. Brad Thompson, President and CEO, will lead the presentation at 11:55 a.m. (5:55 a.m. ET) at the Le Meridien Beach Plaza Hotel in Monte Carlo, Monaco.
The company's clinical program includes Phase I and Phase I/II human trials using REOLYSIN(R), its proprietary formulation of the human reovirus, alone and in combination with radiation.
The presentation and webcast times are subject to change, and investors are advised to log on 15 minutes in advance of the presentation to register and download any necessary software.
Oncolytics' clinical trials are testing the efficacy of REOLYSIN(R) as a cancer treatment, with a focus on the development of oncolytic viruses as potential cancer therapeutics.

Statistics:

The company's clinical program includes multiple Phase I and Phase I/II human trials using REOLYSIN(R).
REOLYSIN(R) is Oncolytics Biotech Inc.'s proprietary formulation of the human reovirus.
The company has established partnerships and collaborations with various organizations to advance the development of REOLYSIN(R) as a cancer treatment.

Sources:

Oncolytics Biotech Inc.

+ Company website: www.oncolyticsbiotech.com

+ Press release: PRNewswire

Rodman & Renshaw 3rd Annual Global Healthcare Conference

+ Event website: N/A

+ Publication details: N/A

The End of American Hypergrowth

For two centuries, the US economy grew by adding workers. That's over.

Healthcare's $5.3 Trillion Drag

How Medical Spending Became America's Biggest Productivity Tax

Breakthrough in Nanotechnology: Electromagnetic Shock Treatment Shows Promise

Researchers at the Wuhan University of Technology in China have made significant progress in the field of nanotechnology, specifically in the area of nanoindentation. A novel electromagnetic shock treatment (EST) method has been developed to enhance the microscale mechanical properties of a titanium alloy, with promising results obtained through array-based

Gut Microbiota Plays Crucial Role in Immunotherapy Success for Colon Cancer Patients

Research investigators at the Zhengzhou Central Hospital Affiliated to Zhengzhou University have made groundbreaking discoveries on the role of gut microbiota in determining the efficacy of immunotherapy for colon cancer patients. The study, which was recently published in Biochimica et Biophysica Acta, reveals that specific bacterial species and microbial metabolites

Read more

The End of American Hypergrowth

Healthcare's $5.3 Trillion Drag

Breakthrough in Nanotechnology: Electromagnetic Shock Treatment Shows Promise

Gut Microbiota Plays Crucial Role in Immunotherapy Success for Colon Cancer Patients